• 1
    Chou R, Croswell JM, Dana T et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 762771
  • 2
    Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981990
  • 3
    Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725732
  • 4
    Crawford ED, Grubb R 3rd, Black A et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011; 29: 355361
  • 5
    Tosoian JJ, Trock BJ, Landis P et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 21852190
  • 6
    Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012; 109: 16481654
  • 7
    NIH State-of-the-Science Conference. Role of Active Surveillance in the Managementof Men With Localized Prostate Cancer. 2011. Available at: Accessed 21 December 2011
  • 8
    Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly : Frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012; 118: 30623070
  • 9
    Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529534
  • 10
    Mitin T, Chen MH, Zhang Y et al. Diabetes Mellitus, Race and the Odds of High Grade Prostate Cancer in Men Treated With Radiation Therapy. J Urol 2011; 186: 22332237
  • 11
    Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000; 164: 388392
  • 12
    Uno H, Nakano M, Ehara H, Deguchi T. Indications for extended 14-core transrectal ultrasound-guided prostate biopsy. Urology 2008; 71: 2327
  • 13
    Eskicorapci SY, Baydar DE, Akbal C et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45: 444448; discussion 8–9
  • 14
    King CR, McNeal JE, Gill H, Presti JC Jr. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys 2004; 59: 386391
  • 15
    Moussa AS, Kattan MW, Berglund R, Yu C, Fareed K, Jones JS. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. BJU Int 2010; 105: 352358
  • 16
    NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer 2011. Available at: Accessed 26 November 2011
  • 17
    Suardi N, Gallina A, Capitanio U et al. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. Cancer 2012; 118: 973980
  • 18
    Walz J, Gallina A, Saad F et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25: 35763581
  • 19
    Litton G, Kane D, Clay G, Kruger P, Belnap T, Parkinson B. Multidisciplinary cancer care with a patient and physician satisfaction focus. J Oncol Pract 2010; 6: e3537
  • 20
    Lu-Yao GL, Albertsen PC, Moore DF et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 12021209
  • 21
    Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 2001; 93: 18221823
  • 22
    Shah JB, McKiernan JM, Elkin EP, Carroll PR, Meng MV. Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. J Urol 2008; 179: 136140
  • 23
    Suardi N, Briganti A, Gallina A et al. Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int 2010; 105: 15481552
  • 24
    Kim JW, Lee HY, Hong SJ, Chung BH. Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J 2004; 45: 671675
  • 25
    de la Rosette JJ, Wink MH, Mamoulakis C et al. Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol. J Urol 2009; 182: 13291336
  • 26
    Nava L, Montorsi M, Consonni P et al. Results of a prospective randomized study comparing 6, 12, 18 transrectal ultrasound guided sextant biopsies in patients with elevated PSA, normal DRE and normal prostatic ultrasound. J Urol 1997; 157 (Suppl.): 59A: 226
  • 27
    Stamatiou K, Alevizos A, Karanasiou V et al. Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int 2007; 78: 313317
  • 28
    Babaian RJ, Toi A, Kamoi K et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152157
  • 29
    Ghani KR, Dundas D, Patel U. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol. BJU Int 2004; 94: 10141020
  • 30
    Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175: 16051612
  • 31
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126131
  • 32
    Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203213
  • 33
    Murphy JX, Xu J, Kochanek KD, and the Division of Vital Statistics. National Vital Statistics Reports. Deaths: Preliminary Data for 2010; 60: 4. Available at: Accessed 30 March 2012